THERAMEX Trademark
THERAMEX is a USPTO trademark filed by Theramex HQ UK Limited. Status: Registered.
Trademark Facts
| Mark | THERAMEX |
|---|---|
| Serial Number | 97583075 |
| Registration Number | 7233958 |
| Status | Registered |
| Filing Date | 2022-09-08 |
| Registration Date | 2023-12-05 |
| Mark Type | Word |
| Nice Classes | 005 (Pharmaceuticals) |
| Owner | Theramex HQ UK Limited |
| Attorney of Record | Leigh Ann Lindquist |
| Prosecution Events | 17 |
| Latest Event | R.PR on 2023-12-05 |
Goods & Services
Anti-fungal pharmaceutical preparations; Contraceptive preparations; contraceptive sponges; chemical contraceptives; oral contraceptives; Dermatological pharmaceutical preparations; Diagnostic preparations for medical purposes; Pharmaceutical preparations and substances for use in relation to women's health, namely, menopause, osteoporosis, uterine fibroids, endometriosis, adenomyosis, menstrual bleeding disorders, fertility, infertility, assisted reproductive technology, IVF; Pharmaceutical preparations and substances containing steroids; Pharmaceutical preparations and substances containing hormones; Pharmaceutical preparations and substances in the nature of hormone replacement therapy; pharmaceutical preparations and substances for use in relation to reproductive health, namely, contraception, menstrual bleeding disorders, fertility, infertility, fertility enhancement preparations, assisted reproductive technology, IVF, miscarriage; pharmaceutical preparations and substances for use in relation to contraception; pharmaceutical preparations and substances for use in relation to conception, namely, contraception, menstrual bleeding disorders, fertility, infertility, fertility enhancement preparations, assisted reproductive technology, IVF, miscarriage; pharmaceutical preparations and substances for use in relation to fertility; fertility enhancement preparations; pharmaceutical preparations and substances for use in relation to the treatment of infertility; pharmaceutical preparations and substances for use in endocrinology; pharmaceutical preparations and substances for use in gynaecology; pharmaceutical preparations and substances for use in rheumatology; pharmaceutical preparations and substances for use in dermatology; Pharmaceutical preparations for the treatment of menopause; Pharmaceutical preparations and substances for the alleviation of menopause-related symptoms; Pharmaceutical preparations and substances for the treatment of osteoporosis; Pharmaceutical preparations and substances for the alleviation of osteoporosis-related symptoms; Pharmaceutical preparations and substances for the treatment of cartilage disorders; Pharmaceutical preparations and substances for the treatment of bone disorders; Pharmaceutical preparations and substances for the treatment of bone loss; Pharmaceutical preparations and substances for the treatment of arthritis; Pharmaceutical preparations and substances for the treatment of calcium deficiency; Pharmaceutical preparations and substances being calcium regulators; Pharmaceutical preparations and substances for the treatment of Paget's disease; Phosphates for pharmaceutical purposes; Self-injectors sold filled with pharmaceutical preparations for the treatment of infertility for subcutaneous injection, osteoporosis; Vitamin supplements; mineral supplements; calcium supplements; all the above being for human use and none being for dental use or for use in relation to oral hygiene